ARIAD Pharmaceuticals, Inc.
MarketLine (a Datamonitor Company)
02 Sep 2014
Available for Immediate Download
ARIAD Pharmaceuticals, Inc. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on ARIAD Pharmaceuticals, Inc. required for business and competitor intelligence needs - Intelligence on ARIAD Pharmaceuticals, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about ARIAD Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: ARIAD Pharmaceuticals (ARIAD) is a biotechnology company that is engaged in the discovery, development and commercialization of small-molecule drugs used in the treatment of cancer. The company's products include ponatinib, ridaforolimus, and AP26113. The company operates in the US and Europe. It is headquartered in Cambridge, Massachusetts, and employs around 300 people. The company recorded revenues of $0.6 million in the fiscal year ended December 2012, a decrease of 97.8% compared to 2011. The company's operating loss was $205.1 million in fiscal 2012, as compared to an operating loss of $76.8 million in 2011. Its net loss was $220.9 million in fiscal 2012, as compared to the net loss of $123.6 million in 2011. Reasons to Purchase: - Gain understanding of ARIAD Pharmaceuticals, Inc. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess ARIAD Pharmaceuticals, Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on ARIAD Pharmaceuticals, Inc. your competitors' business structure, strategy and prospects